Gueye Amadou, Maroun Boutros, Zimur Amol, Berkovits Tom, Tan Shen Mynn
Illumina Inc, San Diego, CA, United States.
Front Oncol. 2024 Jun 21;14:1426558. doi: 10.3389/fonc.2024.1426558. eCollection 2024.
As the projected incidence and mortality of cancer in Sub-Saharan Africa (SSA) rises to epidemic proportions, it is imperative that more is done to identify the genomic differences and commonalities between patients of African and European ancestry to fulfil the promise of precision oncology. Here, we summarize the utility of precision oncology approaches, with a focus on comprehensive genomic profiling (CGP) and consolidate examples of national and international consortia that are driving the field forward. We describe the importance of genomic diversity and its relevance in cancer, and propose recommendations, success factors and desired outcomes for precision oncology consortia to adopt in SSA. Through this, we hope to catalyze the initiation of such projects and to contribute to improving cancer patient outcomes in the region.
随着撒哈拉以南非洲(SSA)地区预计的癌症发病率和死亡率上升到流行程度,必须采取更多措施来确定非洲裔和欧洲裔患者之间的基因组差异和共性,以实现精准肿瘤学的前景。在此,我们总结了精准肿瘤学方法的效用,重点是综合基因组分析(CGP),并整合了推动该领域发展的国家和国际联盟的实例。我们描述了基因组多样性的重要性及其在癌症中的相关性,并为SSA地区的精准肿瘤学联盟提出建议、成功因素和预期成果。通过这样做,我们希望推动此类项目的启动,并为改善该地区癌症患者的治疗结果做出贡献。